News & Events
-
Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
2024/09/02 -
Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the LiverShanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J
2024/05/01 -
SITC-poster：Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy2023/11/05
-
022024/092024/09/02Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
-
012024/052024/05/01Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver
Shanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J
-
052023/112023/11/05SITC-poster：Epigenetic editing as a promising strategy to enhance efficacy and genomic integrity of CAR T cell therapy
-
282023/102023/10/28Epigenic Therapeutics to Present Company's Epigenetic Modulation Technology in Enhancement of CAR-T Function at SITC 2023Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced to present a poster at The Society for Immunotherapy of Cancer（SITC）38th Annual Meeting on November 1-5 at California.
-
272023/102023/10/27ESGCT-poster：Profound and Durable Silencing of PCSK9 in Non-Human Primates by Epigenome Modulation
- 1
- 2
